Every time a study came out that seemed like the nail in the coffin for the so-called horse paste, it rose again, vampire-like, feasting on the blood of social media outrage.
The truth is that while excitement for ivermectin mounted online, it crashed quite quickly in scientific circles. Most randomized trials showed no effect of the drug. A couple of larger trials which seemed to show dramatic effects were subsequently shown to be fraudulent.
Then the TOGETHER trial was published. The 1400-patient study from Brazil, which treated outpatients with COVID-19, found no significant difference in hospitalization or ER visits — the primary outcome — between those randomized to ivermectin vs placebo or another therapy.
A narrative started to develop online — one that is still quite present today — that authorities were suppressing the good news about ivermectin in order to line their own pockets and those of the execs at Big Pharma. The official Twitter account of the FDA clapped back, reminding the populace that we are not horses or cows.
But still, Brazil. Different population than the United States. Different health systems. And very different rates of Strongyloides infections (this is a parasite that may be incidentally treated by ivermectin, leading to improvement independent of the drug's effect on COVID). We all wanted a US trial.
And now we have it. ACTIV-6 was published last week in JAMA, a study randomizing outpatients with COVID-19 from 93 sites around the United States to ivermectin or placebo.
A total of 1591 individuals — median age 47, 60% female — with confirmed symptomatic COVID-19 were randomized from June 2021 to February 2022. About half had been vaccinated.
The primary outcome was straightforward: time to clinical recovery. Did ivermectin make people get better, faster?
It did not. The time to recovery, defined as having three symptom-free days, was 12 days in the ivermectin group and 13 days in the placebo group — that's within the margin of error.
https://jamanetwork.com/journals/jam...rticle/2797483